The long-term clinical outcomes of latanoprostene bunod 0.024% in glaucoma treatment at a tertiary glaucoma center

ABSTRACT

Purpose

To evaluate the clinical outcomes of latanoprostene bunod 0.024% (LB) in intraocular pressure (IOP) control in patients with glaucoma.

Methods

This retrospective cohort study analyzed eyes treated with LB between 01/2018 and 01/2020. Demographic and clinical data were collected at baseline and up to 24-months (mo). Primary outcomes were mean change in IOP (∆IOP) from baseline in eyes switched from a prostaglandin analogue (PGA) to LB (Group 1) vs. eyes in which LB was added as a first PGA to a glaucoma regimen (Group 2).

Results

262 eyes of 162 patients were included. Overall, baseline IOP was 18.67 ± 5.65 mmHg. Group 1 (n = 168 [64%]) and Group 2 (n = 66 [25%]) each individually had significant ∆IOP at 1, 3, 6, 12, and 18 mo compared to baseline (p = 0.005). ∆IOP and duration of IOP control (9.5 ± 11.4 vs. 9.7 ± 9.9 months) on LB was similar between Group 1 and 2 at all time points. Additional pharmacologic or surgical intervention was required in 71 (27%) and 66 (25%) eyes, respectively, and LB was stopped in 24 (9.1%) eyes due to side effects.

Discussion

LB successfully reduced IOP and was well-tolerated in our cohort. PGA naivete does not seem to influence the LB efficacy or its duration of effect.

KEYWORDS:

• Vyzulta
• latanoprostene bunod
• glaucoma
• prostaglandin
• ocular hypertension

Declaration of interest

R Razeghinejad received research support from Olleyes, Equinox, and Allergan. D Lee has received research support from Allergan, Equinox, Glaukos, Mati, Nicox, Olleyes, and Santan, lecture fees from Glaukos, and consulting fees from Quidel Eye Health. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.